OCT 28, 2014 07:00 AM PDT

Quality-by-Design Development of a Purity Method Using ACQUITY UPLC H-Class and QDa Mass Detector

SPONSORED BY: Waters, Waters
Speakers
  • Founders and Managing Directors, Chromicent GmbH
    Biography
      Alexander H. Schmidt has worked 25 years as head of quality control as well as laboratory manager of a development laboratory in a medium-sized, global pharmaceutical company. His expertise lies in the development and validation of analytical methods according to the latest quality-by-design approaches, the qualification of analytical instrument (AIQ), increased efficiency in the laboratory as well as GMP and compliance. Alexander H. Schmidt is the author of more than 50 publications and scientific posters and also a guest lecturer at the Beuth University in Berlin.
       
      Mijo Stanic has worked closely for several years as head of analytical development with Alexander Schmidt. He is an expert in quality-by-design in the development of chromatographic separation methods and mass spectrometry. He is also co-author of numerous publications.

    Abstract:

    Pre-recorded webinar available for immediate playback.

    Traditional method development, in which an LC method is developed principally by trial-and-error, is time consuming and may not result in a robust method. In addition, taking this approach provides no understanding of the influence of key factors on the results. Conversely, modern systematic method development strategies using statistical or modeling software tools to generate experimental designs and explore method robustness offer numerous advantages and can provide a fast and efficient approach for method development.

    Chromicent GmbH (Berlin, Germany) managing directors Alexander Schmidt and Mijo Stanic are experts in the development and validation of analytical methods according to the latest quality-by-design approaches. The aim of their recent work has been to apply quality-by-design principles to build in a more scientific and risk-based, multifactorial strategy in the development of a new UHPLC methods. In this webinar, they will describe the application of their approach in the development of a new purity method for a well known API. The final method, with an analysis time of only 4 minutes, provides a 40-fold increase in productivity compared to the existing method published in the European Pharmacopeia.


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    SEP 12, 2017 08:00 AM PDT
    SEP 12, 2017 08:00 AM PDT
    DATE: September 12, 2017TIME: 8:00am PT, 11:00am ETEvery year, millions of dollars are wasted on poorly characterized and performing antibodies.  Key researchers in the antibody co...
    DEC 11, 2018 10:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 11, 2018 10:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 11, 2018TIME: 11:00 PSTThis webinar will focus on how Reichert's Surface Plasmon Resonance (SPR) systems can generate additional valuable information that is not...
    APR 26, 2018 07:30 AM PDT
    C.E. CREDITS
    APR 26, 2018 07:30 AM PDT
    DATE: April 26, 2018TIME: 07:30am PDT, 04:30pm CESTThe NGS library preparation process is labor-intensive, requiring experience and attention to detail over hours. Eppendorf consumables...
    JUL 27, 2017 09:00 AM PDT
    C.E. CREDITS
    JUL 27, 2017 09:00 AM PDT
    DATE: July 27, 2017TIME: 9:00AM PT, 11:00AM CT, 12:00PM ETDo you have inconsistent results freeze drying samples? Are some of your samples too challenging? Is your freeze dry cycle taki...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    Loading Comments...